前临床皮层的迪诺芬/κ阿片类受体系统调节甲基胺诱导的认知障碍
Ying-Jie Cheng1, Ying-Zhi Deng1, Di Deng1
1Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Addiction biology
|August 30, 2023
概括
长期接触甲基胺 (METH) 会影响认知. 阻断迪诺芬/卡帕阿片类受体 (KOR) 系统,特别是在前临床皮质,可以防止这些METH诱导的认知缺陷.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 成研究 研究成研究
背景情况:
- 长期使用甲基胺 (METH) 会导致持续的认知障碍.
- 内源性迪诺芬/卡帕阿片类受体 (KOR) 系统与压力和成有关.
- 了解涉及METH诱导认知缺陷的特定神经回路至关重要.
研究的目的:
- 研究诺芬/KOR系统在甲基胺诱导的认知障碍中的作用.
- 为了识别特定的大脑区域,当dynorphin/KOR系统被METH激活.
- 评估KOR抗体在缓解METH诱导的认知缺陷方面的治疗潜力.
主要方法:
- 小鼠每天接受METH注射 (10mg/kg) 持续7天,随后进行认知测试 (新物体识别,自发交替).
- 通过使用对手norBNI或通过遗传删除 (KOR淘汰赛小鼠) 来系统地阻止KOR.
- 使用定量PCR测量了dynorphin和KOR mRNA水平,在前皮 (PL) 和下皮 (IL) 中进行区域分析. 还进行了norBNI的局部PL注射.
主要成果:
- 在小鼠中,METH的使用引发了显著的认知障碍.
- 通过norBNI或KOR删除的系统性KOR阻塞可以防止METH诱导的认知缺陷.
- 暴露于METH增加了dynorphin和KORmRNA水平,特别是在前皮层 (PL).
- 将norBNI微注射到PL中可以逆转METH诱导的认知障碍.
结论:
- 在前临界皮层内激活dynorphin/KOR系统是METH诱导认知障碍的关键机制.
- 科尔抗剂显示出神经保护潜力,可以预防与慢性METH滥用相关的认知缺陷.
- 准迪诺芬/KOR通路为治疗药物滥用相关认知功能障碍提供了一个有希望的治疗策略.
相关概念视频
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
230
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
230
Drug Abuse and Addiction: Pharmacological Phenomena
508
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
508
Opioid Receptors: Overview
1.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
1.0K
Adrenergic Agonists: Indirect-Acting Agents
1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K
Analgesia and Pain Management
654
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
654
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K


